- approximately 35% of hemophiliacs were infected with HIV
- approximately 90% of hemophiliacs with severe hemophilia A and 40% of hemophiliacs with severe hemophilia B were infected with HIV
- almost all hemophiliacs who used blood products regularly before 1988 were infected with hepatitis C.
This tragedy forced very rapid changes in the way blood products were manufactured. (See The treatment of hemophilia.)
As a result, there have been no HIV, hepatitis B or hepatitis C infections through factor concentrates in Canada since 1988. Today, plasma-derived clotting factor concentrates are considered to be very safe therapies.
Recombinant clotting factor concentrates have never been known to transmit pathogens of any kind.





